Quilaban and Rocgene introduce iFIND, the new generation of cartridge-based molecular diagnostics, to Portugal

The partnership with Rocgene Technology Limited enables Quilaban to bring iFIND to the Portuguese market — an innovative technology that simplifies and accelerates molecular diagnosis.

Quilaban has established a strategic partnership with Rocgene Technology Limited, a company with almost a decade of expertise in developing molecular diagnostic solutions and reagents. This collaboration will enable the introduction of iFIND* to Portugal — a next-generation cartridge-based molecular diagnostic system that combines speed, simplicity, scalability, and reliability.

iFIND is a compact and fully automated instrument that integrates cartridge-based PCR technology designed to overcome the limitations of traditional methods, providing results from a sample with just one click. This “one button to result” process eliminates complex steps, reducing turnaround times and allowing healthcare professionals to focus on what truly matters: patient care.

Beyond its speed, the iFIND technology offers high sensitivity and specificity, ensuring reliable diagnostics across diverse clinical settings. It features a broad and versatile test menu covering key areas such as mycobacteria, healthcare-associated infections, respiratory and gastrointestinal infections, among others. The related tests and consumables are professional-use in vitro diagnostic medical devices, developed to meet rigorous standards of quality and safety.

Through this partnership, Quilaban reinforces its commitment to innovation and to providing access to advanced diagnostic solutions, contributing to more efficient, agile, and patient-centred healthcare.

 * Rocgene iFIND is an in vitro diagnostic medical device for professional use. Please read the information contained in the labelling and user manual carefully for information, warnings and precautions relating to the use of the devices.